Home » Stocks » RDY

Dr. Reddy's Laboratories Ltd. (RDY)

Stock Price: $65.37 USD 1.04 (1.62%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 10.87B
Revenue (ttm) 2.32B
Net Income (ttm) 258.59M
Shares Out 166.28M
EPS (ttm) 1.40
PE Ratio 46.69
Forward PE 32.15
Dividend $0.33
Dividend Yield 0.50%

Stock Quote

Trading Day November 27
Last Price $65.37
Previous Close $64.33
Change ($) 1.04
Change (%) 1.62%
Day's Open 64.74
Day's Range 64.67 - 65.57
Day's Volume 90,484
52-Week Range 33.33 - 73.50

More Stats

Market Cap 10.87B
Enterprise Value 10.82B
Earnings Date (est) Feb 4, 2021
Ex-Dividend Date Jul 10, 2020
Shares Outstanding 166.28M
Float 166.20M
EPS (basic) n/a
EPS (diluted) 1.40
FCF / Share 2.57
Dividend $0.33
Dividend Yield 0.50%
Earnings Yield 2.14%
FCF Yield 3.93%
Payout Ratio 17.10%
Shares Short 796,316
Short Ratio 4.41
Short % of Float 0.48%
Beta -0.01
PE Ratio 46.69
Forward PE 32.15
P/FCF Ratio 25.43
PS Ratio 4.69
PB Ratio 4.79
Revenue 2.32B
Operating Income 212.11M
Net Income 258.59M
Free Cash Flow 427.47M
Net Cash 48.25M
Net Cash / Share 0.29
Gross Margin 53.84%
Operating Margin 9.16%
Profit Margin 11.20%
FCF Margin 18.46%
ROA 8.03%
ROE 9.63%
ROIC 12.60%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (35)

Buy 19
Overweight 8
Hold 7
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$74.63*
(14.17% upside)
Low
53.9
Current: $65.37
High
86.6
Target: 74.63
*Average 12-month USD price target from 34 stock analysts.

Financial Performance

Financial numbers in millions INR.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue174,600153,851142,028140,809154,708148,189132,170116,26696,73774,693
Revenue Growth13.49%8.32%0.87%-8.98%4.4%12.12%13.68%20.19%29.51%-
Gross Profit94,00983,43076,30478,35692,28185,40375,80160,57953,30540,263
Operating Income15,99320,88811,91713,49829,61926,28626,03221,11218,25212,629
Net Income19,49818,7959,80612,03920,01322,17921,51516,77714,26211,040
Shares Outstanding166166166167171170170170169169
Earnings Per Share117.40113.0959.0072.09116.98129.75126.0498.4483.8164.95
EPS Growth3.81%91.68%-18.16%-38.37%-9.84%2.94%28.04%17.46%29.04%-
Dividend Per Share0.270.290.290.300.290.590.260.230.900.24
Dividend Growth-8.56%0.69%-2.36%1.71%-50.17%121.97%15.28%-74.64%276.25%-
Operating Cash Flow36,94633,54520,79027,28348,26130,43126,55018,85420,6988,009
Capital Expenditures-4,715-5,690-9,152-12,234-11,933-9,167-9,996-6,606-6,816-8,718
Free Cash Flow32,23127,85511,63815,04936,32821,26416,55412,24813,882-709
Cash & Equivalents25,74024,75720,96818,13639,95539,65333,53422,09918,1525,762
Total Debt22,10238,38150,71449,18533,51343,12644,74236,76032,21023,572
Net Cash / Debt3,638-13,624-29,746-31,0496,442-3,473-11,208-14,661-14,058-17,810
Assets232,241225,427225,604219,821207,650194,762170,223142,369119,47795,005
Liabilities77,25385,23099,14495,77779,31483,46079,42269,56462,03349,015
Book Value154,988140,197126,460124,044128,336111,30290,80172,78557,44445,990
Numbers in millions INR, except per-share numbers.

Company Profile

Company Details

Full Name Dr. Reddy's Laboratories Ltd.
Country India
Employees 21,650
CEO Erez Israeli

Stock Information

Ticker Symbol RDY
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: RDY

Description

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists; and partnership with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India. The company was founded in 1984 and is headquartered in Hyderabad, India.